MARKET

ABP

ABP

ABPRO HLDGS INC
NASDAQ
0.4116
-0.0004
-0.10%
Opening 13:08 03/27 EDT
OPEN
0.4116
PREV CLOSE
0.4120
HIGH
0.4349
LOW
0.4116
VOLUME
28.25K
TURNOVER
--
52 WEEK HIGH
13.00
52 WEEK LOW
0.4100
MARKET CAP
21.39M
P/E (TTM)
-1.4346
1D
5D
1M
3M
1Y
5Y
1D
Abpro Holdings to Present Preclinical Data at AACR 2025
TipRanks · 1d ago
BRIEF-ABPRO Announces Oral Presentation Of First Preclinical Data For ABP-102/CT-P72, A Tetravalent Bispecific HER2 X CD3 T-Cell Engager, At AACR Annual Meeting 2025
Reuters · 2d ago
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
Barchart · 2d ago
Weekly Report: what happened at ABP last week (0317-0321)?
Weekly Report · 3d ago
Weekly Report: what happened at ABP last week (0310-0314)?
Weekly Report · 03/17 10:23
*Abpro Holdings Announces Departure of CEO Ian Chan >ABP
Dow Jones · 03/10 22:36
ABPRO STATEMENT ON THE DEPARTURE OF FORMER CEO IAN CHAN
Reuters · 03/10 22:35
Press Release: Abpro Statement on the Departure of Former CEO Ian Chan
Dow Jones · 03/10 22:34
More
About ABP
Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The Company is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.

Webull offers ABPRO Holdings Inc stock information, including NASDAQ: ABP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABP stock methods without spending real money on the virtual paper trading platform.